

BIO-TECHNE Corp
Form 8-K
September 05, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 5, 2018

BIO-TECHNE CORPORATION

(Exact Name of Registrant as Specified in its Charter)

| | | |
|---|--------------------------|--|
| Minnesota | 0-17272 | 41-1427402 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |

614 McKinley Place NE

Minneapolis, MN 55413

(Address of Principal Executive Offices) (Zip Code)

(612) 379-8854

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

As described in this Current Report, effective in the first quarter of fiscal year 2019, Bio-Techne Corporation. (“Bio-Techne” or “the company”) changed its reportable segments due to recent changes in its underlying organizational model designed to support the business following recent acquisitions and to facilitate global growth. This Current Report recasts previously issued financial information and does not represent a restatement. The information contained in this Form 8-K is being furnished in order to provide the financial community with historical financial data that is presented on a basis consistent with the Company’s new reporting structure. Bio-Techne did not operate under the realigned reportable segment structure for any of these prior periods and will begin to report comparative results under the new structure effective with the filing of its Quarterly Report on Form 10Q for the quarter ended September 30, 2018.

The information in this Form 8-K, including the exhibit attached hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Supplemental Historical Business Segment Net Sales and Operating Income for Bio-Techne Corporation for 99.1 each of the quarterly periods ended September 30, December 31, March 31, and June 30, 2018 and 2017 and for the years ended June 30, 2018 and 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-TECHNE CORPORATION

By: /s/ Brenda S. Furlow

Date: September 5, 2018 Brenda S. Furlow

Senior Vice President, General Counsel and Secretary

EXHIBIT INDEX

Exhibit
No. Description

99.1 Supplemental Historical Business Segment Net Sales and Operating Income for Bio-Techne Corporation for each of the quarterly periods ended September 30, December 31, March 31, and June 30, 2018 and 2017 and for the years ended June 30, 2018 and 2017.

